Valneva SE

Founded in Saint-Herblain, France, in 1998, Valneva SE operates as a specialized biotechnology firm, concentrating on the creation and global distribution of preventative vaccines. Its primary focus is on infectious diseases for which current medical solutions are inadequate. The company's commercialized vaccine offerings for international travelers include IXIARO, an inactivated vaccine derived from Vero cell culture, which provides active immunity against Japanese encephalitis. Also available is DUKORAL, an oral vaccine designed to guard against diarrhea caused by Vibrio cholera and/or enterotoxigenic Escherichia coli that produces heat-labile toxin. Valneva additionally developed VLA2001, a vaccine targeting SARS-CoV-2. In its development pipeline, Valneva is advancing VLA15, a vaccine candidate for Borrelia, which has successfully concluded Phase II clinical trials. Another key candidate is VLA1553, currently undergoing Phase III clinical trials for the prevention of the chikungunya virus. Valneva distributes its pharmaceutical products across a wide geographic footprint, including the United States, Canada, Germany, Austria, the Nordic countries, the United Kingdom, other European nations, and various international markets. The company maintains significant partnerships, such as a collaboration with Pfizer, Inc. for the co-development and commercialization of its Lyme disease vaccine, and an alliance with Instituto Butantan for the development, manufacture, and distribution of a single-shot chikungunya vaccine.